On ECHEMI
Home > Drugs > Anhui Renhe Pharmaceutical Co., Ltd.
Anhui Renhe Pharmaceutical Co., Ltd.
  • Founded in:

    1991-12-15
  • Country:

    China China
  • Address:

    No. 27 Xinyang Avenue, Fuyang Economic and Technological Development Zone
  • Tax NO.:

    913412007349648451
  • Registered Funds:

    16.8 million yuan
  • Website:

  • Email:

Related Drugs
Berberine Hydrochloride Tablets
Each tablet of this product contains 0.1g of berberine hydrochloride as the main ingredient, and the auxiliary materials are starch, hydroxypropyl cellulose, micro-powder silica gel, magnesium stearate, sucrose, talcum powder, dextrin, pigment, and tartrazine. Chemical name: berberine hydrochloride Molecular formula: C20H18C1NO4 Molecular weight: 371.82
Name Description Content CAS NO. Registered Holders
Berberine hydrochloride

Effective for intestinal infections caused by Shigella dysenteriae and Escherichia coli

More

Effective for intestinal infections caused by Shigella dysenteriae and Escherichia coli

0.1g 633-65-8 46
Ibuprofen tablets
Ibuprofen
Name Description Content CAS NO. Registered Holders
Ibuprofen

This product can inhibit the synthesis of prostaglandins and has antipyretic, analgesic and anti-inflammatory effects.

More

This product can inhibit the synthesis of prostaglandins and has antipyretic, analgesic and anti-inflammatory effects.

15687-27-1 53
Large Hawthorn Granules
Hawthorn, malt (fried), Liushenqu (fried with bran). Auxiliary ingredients are sucrose and citric acid.
Name Description Content CAS NO. Registered Holders
Hawthorn

0
Malt (roasted)

0
Liu Shenqu (fried with bran)

0
Sucrose

57-50-1 72
Citric acid monohydrate

5949-29-1 39
Nifedipine Tablets
The main ingredient of this product is nifedipine.
Name Description Content CAS NO. Registered Holders
Nifedipine

By blocking the membrane transport of calcium ions in myocardial and vascular smooth muscle, inhibiting the influx of calcium ions into cells, it causes a decrease in myocardial contractility and vasodilation. Animal experiments have shown that by reducing myocardial contractility and peripheral vascular resistance, myocardial oxygen consumption is reduced; by dilating coronary vessels and developing collateral circulation, the oxygen supply to myocardial ischemic sites is increased; by inhibiting the consumption of high-energy phosphate compounds, the ability to resist hypoxia is enhanced.

More

By blocking the membrane transport of calcium ions in myocardial and vascular smooth muscle, inhibiting the influx of calcium ions into cells, it causes a decrease in myocardial contractility and vasodilation. Animal experiments have shown that by reducing myocardial contractility and peripheral vascular resistance, myocardial oxygen consumption is reduced; by dilating coronary vessels and developing collateral circulation, the oxygen supply to myocardial ischemic sites is increased; by inhibiting the consumption of high-energy phosphate compounds, the ability to resist hypoxia is enhanced.

21829-25-4 75
Kitasamycin Tablets
Kitasamycin
Name Description Content CAS NO. Registered Holders
Sineptina

This product is a macrolide antibiotic with the same mechanism of action as erythromycin and a similar antibacterial spectrum as erythromycin. Its antibacterial activity against most Gram-positive bacteria is slightly poorer, and some erythromycin-resistant Staphylococcus aureus are still sensitive to kitasamycin. This product also has considerable activity against diphtheria, tetani, Neisseria gonorrhoeae, Bordetella pertussis, Rickettsia and Chlamydia trachomatis.

More

This product is a macrolide antibiotic with the same mechanism of action as erythromycin and a similar antibacterial spectrum as erythromycin. Its antibacterial activity against most Gram-positive bacteria is slightly poorer, and some erythromycin-resistant Staphylococcus aureus are still sensitive to kitasamycin. This product also has considerable activity against diphtheria, tetani, Neisseria gonorrhoeae, Bordetella pertussis, Rickettsia and Chlamydia trachomatis.

1392-21-8 8
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.